Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bausch Health Companies Inc.

https://www.bauschhealth.com/

Latest From Bausch Health Companies Inc.

Contaminated Eye Drops Return To US FDA’s View

FDA says FivFivGo, Rebright and South Moon are copycats in packaging easily mistaken for Lumify OTC eye drops. Testing found South Moon contaminated with bacteria linked to an antibiotic-resistant infection; agency warns using any of the three poses risk of eye infection.

OTC Drugs Warning Letters

Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances

More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.

Scrip Asks Advanced Therapies

Deal Watch: Ikena Cuts Staff After BMS Exits IO Partnership

Plus deals involving Lipocine/Verity, Vivtex/AI Proteins, Windtree/Lee’s Pharmaceutical, Biogen/Ji Xing, Sermonix/Henlius and news from the world of technology transfer.

Deal Watch Business Strategies

J.P. Morgan Day One: Novartis Reveals Two Deals, Pfizer's Bad Year, Bristol's Wobbly Growth

Daily notebook from the J.P. Morgan Healthcare Conference: Deal and strategy news from Novartis, BMS and Pfizer; Gilead talks lenacapavir PrEP launch plans; BioMarin's new CEO makes an appearance and Saunders explains the status at Bausch + Lomb.

Deals Strategy
See All

Company Information

  • Industry
  • Medical Devices
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
    • OTC, Consumer
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
  • Other Names / Subsidiaries
    • AB Sanitas
    • Afexa Life Sciences Inc.
    • Amoun Pharmaceutical
    • Aton Pharma, Inc.
    • Bausch Health Ireland Limited
    • Bausch + Lomb Holding International
    • Biovail Corporation
    • Callisto Pharmaceuticals, Inc. Dendreon Corporation
    • Dermik Laboratories, Inc.
    • Dow Pharmaceutical Sciences, Inc.
    • Eyetech Inc.
    • Graceway Pharmaceuticals, LLC
    • ICN Pharmaceuticals, Inc.
    • iNova Diagnostics, Inc.
    • Instituto Terapeutico Delta Ltda
    • Medicis Aesthetics Holdings Inc
    • Medicis Pharmaceutical Corporation
    • Mercury (Cayman) Holdings
    • OraPharma, Inc.
    • Ortho Dermatologics
    • Prestwick Pharmaceuticals, Inc.
    • PharmaSwiss S.A.
    • Pedinol Pharmacal, Inc.
    • Salix Pharmaceuticals Ltd. (InKine Pharmaceutical
    • Oceana Therapeutics, LLC
    • Q-Med Scandinavia, Inc.
    • Santarus, Inc.)
    • Sanitas AB
    • Solta Medical, Inc.
    • SPI Pharmaceuticals Inc
    • Synergetics USA, Inc.
    • Synergy Pharmaceuticals Inc.(SGYP)
    • Technolas Perfect Vision GmbH (TPV)
    • Ucyclyd Pharma, Inc.
    • Unilens Vision, Inc.
    • Viratek Pharma Inc
    • Valeant Pharmaceuticals International, Inc.
    • Xcel Pharmaceuticals, Inc.
UsernamePublicRestriction

Register